Lifeboat Foundation

A gene editing tool using a system known as CRISPR-Cas9 has recently been approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease. The drug is known as Casgevy and the media has hailed this treatment as a ‘cure’ for sickle cell anemia patients. While it is still unclear if the drug completely cures these patients, clinical trials show exciting efficacy.

Sickle cell disease is a genetic blood disorder affecting thousands of US citizens. Many of these patients are African American and Hispanic. In sickle cell disease, hemoglobin, a protein in red blood cells that helps carry oxygen throughout the body, is mutated. As a result, blood cells change shape in the form of a sickle, giving the disease its name. Unfortunately, the mutated cells cause disruption of blood flow and prevent other blood cells from delivering oxygen to the body. This disease is extremely rare and can lower the quality of life in patients. Previously, there were limited treatments options including transfusions and medications for pain management. However, Casgevy provides a new option to help treat the patient and relieve pain for over a year after a single treatment.

One-time treatment using Casgevy improved life quality for sickle cell patients. A single-arm trial was conducted at multiple health centers in adults and adolescents. These patients were screened for two vaso-occlusive crises (VOCs) which are described as severely painful events due to a lack of oxygen delivery from sickle cell blood cells blocking blood flow. The primary measure of success in the trial was the number of VOCs after treatment. In total, 44 patients received Casgevy and 33 were able to follow up and be evaluated. Of the 33 patients that made it through the trial, 29 of them did not experience any VOCs for 12 months. This is a 93.5% success rate based on the number of patients that were analyzed. All 44 patients were able to successfully undergo treatment without any graft rejection. In addition, researchers concluded that this treatment was not only effective, but safe with few side effects.

Our very old immune systems can’t keep up with modern lifestyles and diets, leading to increases in all sorts of chronic health problems like allergies and obesity.

In a recent study, researchers found a new way to change the physical properties of a specific protein known to be the culprit of about 75% of all human cancer cases. The researchers say the discovery could pave the way for future cancer treatments.

Hybrid Intelligence, an emerging field at the intersection of human intellect and artificial intelligence (AI), is redefining the boundaries of what can be achieved when humans and machines collaborate. This synergy leverages the creativity and emotional intelligence of humans with the computational power and efficiency of machines. Let’s explore how hybrid intelligence is augmenting human capabilities, with real examples and its impacts on the human workforce.

Hybrid intelligence is not just about AI assisting humans; it’s a deeper integration where both sets of intelligence complement each other’s strengths and weaknesses. While AI excels in processing vast amounts of data and pattern recognition, it lacks the emotional intelligence, creativity, and moral reasoning humans possess. Hybrid systems are designed to capitalize on these respective strengths, leading to outcomes that neither could achieve alone.

In the healthcare sector, hybrid intelligence is enhancing diagnostic accuracy and treatment efficiency. IBM’s Watson Health, for example, assists doctors in diagnosing and developing treatment plans for cancer patients. By analyzing medical literature and patient data, Watson provides recommendations based on the latest research, which doctors then evaluate and contextualize based on their professional judgment and patient interaction.

In today’s column, I am continuing my ongoing series about the impact of generative AI in the health and medical realm.

You can use generative AI to analyze your sleeping dreams, but do so with caution and a keen eye. This close up look tells you how to best proceed.

A collaborative study by the UTokyo-KI LINK program, headed by Camilla Björkegren from Karolinska Institutet, Kristian Jeppsson and Katsuhiko Shirahige from The University of Tokyo shows that a protein complex named Smc5/6 binds DNA structures called positive supercoils. These form when the chromosomal DNA double helix folds onto itself due to overtwisting caused by transcription, which is the first step in gene expression.

The study presents in vivo data indicating that Smc5/6 binds to the base of chromosome loops in regions that contain high levels of transcription-induced positive supercoils. The complex is also shown to control the three-dimensional (3D) organization of these regions.

Computational machine learning provides additional results supporting that transcription-induced positive supercoils determine the chromosomal binding pattern of Smc5/6. Finally, in vitro single molecule analysis, performed by the team of Dr. Eugene Kim at Max Planck Institute in Frankfurt, provides direct evidence that Smc5/6 preferentially binds positive DNA supercoils.

“Soilless biofortification of vegetables has opened the door to the potential for adapting vegetable production to specific dietary requirements,” said Dr. Massimiliano Renna.

Can microgreen be customized based on dietary and medical needs? This is what a recent study published in the Journal of the Science of Food and Agriculture hopes to address as a collaborative team of Italian researchers investigated the potential for customizing microgreens via soilless growing methods designed to suit specific dietary needs based on medical concerns. This study holds the potential to help scientists and patients better understand the available nutritional options, specifically for medical reasons.

“Propelled by an ever-growing awareness of the importance of following dietary recommendations, interest in personalized nutrition is on the rise. Soilless biofortification of vegetables has opened the door to the potential for adapting vegetable production to specific dietary requirements,” said Dr. Massimiliano Renna, who is a professor of agricultural and environmental science at the University of Bari Aldo Moro and a co-author on the study.

Continue reading “Customized Microgreens: A Breakthrough in Personalized Nutrition” »

Not all software is perfect—many apps, programs, and websites are released despite bugs. But the software behind critical systems like cryptographic protocols, medical devices, and space shuttles must be error-free, and ensuring the absence of bugs requires going beyond code reviews and testing. It requires formal verification.

Formal verification involves writing a mathematical proof of your code and is “one of the hardest but also most powerful ways of making sure your code is correct,” says Yuriy Brun, a professorat the University of Massachusetts Amherst.

To make formal verification easier, Brun and his colleagues devised a new AI-powered method called Baldur to automatically generate proofs. The accompanying paper, presented in December 2023 at the ACM Joint European Software Engineering Conference and Symposium on the Foundations of Software Engineering in San Francisco, won a Distinguished Paper award. The team includes Emily First, who completed the study as part of her doctoral dissertation at UMass Amherst; Markus Rabe, a former researcher at Google, where the study was conducted; and Talia Ringer, an assistant professor at the University of Illinois Urbana-Champaign.

Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (WHO), will be joined by policymakers and members of the health industry to consider how to prepare for the emergence of an unknown pathogen.

Michel Demaré, chair of the board of pharmaceutical giant AstraZeneca, Brazilian health minister Nisia Trindade Lima and two other executives will also be on the panel, as will Shyam Bishen, a New York-based healthcare executive and member of the WEF’s executive committee.

He told CNBC on Monday that the forum had calculated that preparing the global health system for another pandemic would require “close to a trillion dollars,” describing the topic as a “big question.”